Searle/Pfizer Celebrex
Executive Summary
FDA Arthritis Advisory Committee will meet Dec. 1 to discuss cyclooxygenase-2 inhibitor celecoxib for acute or chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis and for the management of pain. The meeting will begin at 8:00 a.m. at the Town Center Hotel in Silver Spring, Md. The committee will meet in a closed session Dec. 2 to discuss trade secrets